Background: Prostatic Specific Antigen (PSA), a helpful tumor maker in the diagnosis of prostate cancer, may rise due to many causes such as Digital Rectal Examination (DRE), Acute Urinary Retention (AUR), ect. Objective: To evaluate on the influences of some factors on the serum PSA level in Benign Prostatic Hyperplasia (BPH). Subjects and method: This study included 122 men who were diagnosed BPH with a mean age of 71.18 +/- 7.19 years (ranged 54-92). The patients were divided into 3 groups: DRE group included 60 patients, their blood samples were obtained before and after 24 hours; catheterization group included 35 patients who presented with AUR, their PSA values were determined before 48 hours and 2 weeks after elevation; the inflammation group consisted of 27 patients with symptoms of acute urinary tract infections, the PSA levels were evaluated before 48 hours and 4 weeks after anti-inflammatory therapy. Results: The PSA levels increased significantly in patients with larger prostate sizes (p<0.01, r = 0.492). PSA level tended to increase with age (p<0.05, r = 0.29). The PSA values changed 14.72 +/- 10.85% after DRE (p<0.05). After relief of urethral catheterization, PSA levels decreased 50.77 +/- 20.42% (p<0.05). After anti-inflammatory therapy, 51.59 +/- 21.87% (p<0.05). Conclusions: These results suggested that it may be the best way to perform DRE after obtaining serum PSA for analysis. Serum PSA concentration should not be determined when AUR and acute urinary tract infection.
Benign prostatic hyperplasia ; PSA

Background: Interstitial Laser Coagulation (ILC) Indigo 830e system is the first technique that is used in Viet Nam for the treatment of Benign Prostatic Hyperplasia (BPH) patients. Objectives: (1) To evaluate the effects of treatment of benign prostatic hyperplasia by ILC Indigo 830e system. (2) To describe peri- and post-proceduce complications. Subjects and method: The study consisted of 106 BPH patients who treated by ILC Indigo 830e system. This was a cross-section, descriptive study. Results: Overally, good and moderate outcomes was 94.8%, unsatisfactory was 5.2%. The peri- and post-proceduce complications were: urethral irritability 20.8%, prolonged catheterization 4.7%, urinary tract infections 4.7% and hematuria 0.94%. Conclusion: The treatment for benign prostatic hyperplasia patients by ILC Indigo 830e system was an effective and safe therapy, especially in elderly patient group who had multiple diseases.
Benign prostatic hyperplasia ; interstitial laser coagulation

No abstract available.
Prostatic Hyperplasia

No abstract available.
Prostatic Hyperplasia*

No abstract available.
Prostatic Hyperplasia*

No abstract available.
Hyperplasia* ; Prostate* ; Prostatic Hyperplasia ; Prostatic Neoplasms

The study was made on 42 benign prostatic hyperplasia patients. The results showed that after one month therapy by traditional medication, symptoms scoring index IPSS reduced from 21.0 to 11.71 (p<0.05). The flow of urinary increased from 4.56ml/s to 8.98ml/s (p<0.05). Residual urine volume reduced from 16.52ml to 8.35ml (p<0.05). The therapeutic outcomes by the extract of "Than khi hoan gia giam" were classified as follows: Good in 23 cases (54.8%), Moderate in 15 cases (35.7%), Poor in 4 cases (9.5%).
Prostatic Hyperplasia ; Therapeutics ; Prostatic Hyperplasia ; Medicine, Traditional

No abstract available.
Prostatectomy* ; Prostatic Hyperplasia

The clinical effect of prazosin, an alpha-1-receptor blocking agent, was studied in 31 patients with benign prostatic hypertrophy. The daily dose of 1.5-6 mg of prazosin was given for 2 weeks to 3 months. The efficacy was assessed by using uroflowmetry calculated from maximum flow rate, average flow rate and residual urine volume. The result revealed significant improvement of day time frequency, night time frequency (p<0.05) and maximum and average flow rate (p<0.05). It was suspected that prazosin was the valuable alpha-1-receptor blocker for benign prostatic hypertrophy and worth while to initiate medical treatment before undergoing any surgical intervention or when surgery is contraindicated.
Humans ; Prazosin* ; Prostatic Hyperplasia*

No abstract available.
Humans ; Male* ; Prostatic Hyperplasia*